SI3043775T1 - Tekoče proteinske formulacije, ki vsebujejo sredstva za zniževanje viskoznosti - Google Patents

Tekoče proteinske formulacije, ki vsebujejo sredstva za zniževanje viskoznosti

Info

Publication number
SI3043775T1
SI3043775T1 SI201431702T SI201431702T SI3043775T1 SI 3043775 T1 SI3043775 T1 SI 3043775T1 SI 201431702 T SI201431702 T SI 201431702T SI 201431702 T SI201431702 T SI 201431702T SI 3043775 T1 SI3043775 T1 SI 3043775T1
Authority
SI
Slovenia
Prior art keywords
formulations containing
lowering agents
protein formulations
liquid protein
containing viscosity
Prior art date
Application number
SI201431702T
Other languages
English (en)
Inventor
Alyssa M. Larson
Kevin Love
Alisha K. Weight
Alan Crane
Robert S. Langer
Alexander M. Klibanov
Original Assignee
Eagle Biologics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Biologics, Inc. filed Critical Eagle Biologics, Inc.
Publication of SI3043775T1 publication Critical patent/SI3043775T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61G—TRANSPORT, PERSONAL CONVEYANCES, OR ACCOMMODATION SPECIALLY ADAPTED FOR PATIENTS OR DISABLED PERSONS; OPERATING TABLES OR CHAIRS; CHAIRS FOR DENTISTRY; FUNERAL DEVICES
    • A61G3/00—Ambulance aspects of vehicles; Vehicles with special provisions for transporting patients or disabled persons, or their personal conveyances, e.g. for facilitating access of, or for loading, wheelchairs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
SI201431702T 2013-09-11 2014-09-11 Tekoče proteinske formulacije, ki vsebujejo sredstva za zniževanje viskoznosti SI3043775T1 (sl)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201361876621P 2013-09-11 2013-09-11
US201461940227P 2014-02-14 2014-02-14
US201461943197P 2014-02-21 2014-02-21
US201461946436P 2014-02-28 2014-02-28
US201461988005P 2014-05-02 2014-05-02
US201462008050P 2014-06-05 2014-06-05
US201462026497P 2014-07-18 2014-07-18
US201462030521P 2014-07-29 2014-07-29
EP14776954.1A EP3043775B1 (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents
PCT/US2014/055254 WO2015038818A2 (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents

Publications (1)

Publication Number Publication Date
SI3043775T1 true SI3043775T1 (sl) 2021-01-29

Family

ID=51626611

Family Applications (4)

Application Number Title Priority Date Filing Date
SI201431701T SI3043774T1 (sl) 2013-09-11 2014-09-11 Tekoče proteinske formulacije, ki vsebujejo ionske tekočine
SI201432065T SI3043776T1 (sl) 2013-09-11 2014-09-11 Tekoče proteinske formulacije, ki vsebujejo vodotopna organska barvila
SI201432039T SI3043772T1 (sl) 2013-09-11 2014-09-11 Tekoče proteinske formulacije, ki vsebujejo organofosfate
SI201431702T SI3043775T1 (sl) 2013-09-11 2014-09-11 Tekoče proteinske formulacije, ki vsebujejo sredstva za zniževanje viskoznosti

Family Applications Before (3)

Application Number Title Priority Date Filing Date
SI201431701T SI3043774T1 (sl) 2013-09-11 2014-09-11 Tekoče proteinske formulacije, ki vsebujejo ionske tekočine
SI201432065T SI3043776T1 (sl) 2013-09-11 2014-09-11 Tekoče proteinske formulacije, ki vsebujejo vodotopna organska barvila
SI201432039T SI3043772T1 (sl) 2013-09-11 2014-09-11 Tekoče proteinske formulacije, ki vsebujejo organofosfate

Country Status (16)

Country Link
US (11) US9833513B2 (sl)
EP (7) EP3043772B1 (sl)
JP (11) JP6412575B2 (sl)
KR (5) KR20240042200A (sl)
CN (7) CN110559435B (sl)
AU (10) AU2014318696B2 (sl)
CA (4) CA2923843C (sl)
ES (3) ES2959451T3 (sl)
HK (5) HK1225981A1 (sl)
IL (3) IL244430B (sl)
MX (6) MX2016003183A (sl)
RU (2) RU2710542C2 (sl)
SG (6) SG11201601730TA (sl)
SI (4) SI3043774T1 (sl)
WO (4) WO2015038818A2 (sl)
ZA (4) ZA201601968B (sl)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011226672B2 (en) 2010-03-12 2015-07-23 Immunogen, Inc. CD37-binding molecules and immunoconjugates thereof
JP6018622B2 (ja) 2011-04-01 2016-11-02 イミュノジェン， インコーポレイテッド Ｃｄ３７結合性分子及びその免疫複合体
US20140348719A1 (en) * 2013-03-14 2014-11-27 Bureau Veritas Pharmaceutical compound stabilizing filter compositions and methods of making and using same
CN110559435B (zh) 2013-09-11 2023-10-20 伊戈尔生物药品股份有限公司 包含离子性液体的液体蛋白质制剂
JP2017507900A (ja) * 2013-12-17 2017-03-23 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US20160074515A1 (en) * 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US11471479B2 (en) * 2014-10-01 2022-10-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
AU2016276158B2 (en) * 2015-06-08 2022-06-30 Debiopharm International, S.A. Anti-CD37 immunoconjugate and anti-CD20 antibody combinations
AU2016280070B2 (en) 2015-06-17 2022-09-15 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists and taxanes
TW202330904A (zh) * 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
US11104740B2 (en) 2015-08-28 2021-08-31 Debiopharm International, S.A. Antibodies and assays for detection of CD37
WO2017049205A2 (en) * 2015-09-18 2017-03-23 Amunix Operating Inc. Growth hormone formulation
WO2017055966A1 (en) * 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
CA3129181C (en) * 2015-10-23 2023-10-31 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US10407510B2 (en) * 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
CN109152831A (zh) * 2015-12-29 2019-01-04 安口生物公司 贝伐珠单抗的缓冲制剂
CN105699555B (zh) * 2016-03-24 2018-09-11 中国标准化研究院 一种丙烯基乙基愈创木酚的液相色谱制备方法
AU2017257505B2 (en) * 2016-04-25 2020-05-14 Medimmune, Llc Compositions comprising coformulation of anti-PD-L1 and Anti-CTLA-4 antibodies
MX2018013523A (es) * 2016-05-05 2019-06-10 Univ Pennsylvania Anticuerpos monoclonales de adn dirigidos a il-6 y cd126.
EA201990316A1 (ru) * 2016-08-18 2019-07-31 Ридженерон Фармасьютикалз, Инк. Анализ для определения потенциала самоассоциации белка с использованием концентрационно-зависимой спектроскопии самовзаимодействия на основе наночастиц
US11274289B1 (en) 2016-10-04 2022-03-15 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US10463733B1 (en) 2016-10-04 2019-11-05 United States of America as represented by the Secetary of the Air Force Ultra-stable protein ionic liquids
US11274163B1 (en) 2016-10-04 2022-03-15 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US11382976B1 (en) 2016-10-04 2022-07-12 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US11274137B1 (en) 2016-10-04 2022-03-15 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US11385201B1 (en) 2019-09-30 2022-07-12 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
JP7116725B2 (ja) * 2016-10-27 2022-08-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 アルツハイマー病を治療するための抗ａベータプロトフィブリル抗体及びベータ－セクレターゼｂａｃｅ１阻害剤を含む組成物
CN116407644A (zh) * 2016-11-02 2023-07-11 波拉里集团 聚乙二醇化精氨酸脱亚氨酶的调配物
JP2020510608A (ja) 2016-11-02 2020-04-09 デビオファーム インターナショナル， エス． アー． 抗ｃｄ３７イムノコンジュゲート療法を改善するための方法
EP3582801A4 (en) * 2017-02-16 2020-12-23 Reform Biologics LLC EXCIPIENT COMPOUNDS INTENDED FOR PROTEIN TREATMENT
JOP20190204A1 (ar) * 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
US9901545B1 (en) 2017-04-13 2018-02-27 Richard C. Fuisz Method and composition for making an oral soluble film, containing at least one active agent
US10238600B2 (en) 2017-04-13 2019-03-26 Richard C. Fuisz Package, system and methods for custody and control of drugs, and method and composition for making an oral soluble film, containing at least one active agent
EP3612217A4 (en) * 2017-04-18 2020-12-30 Dr. Reddy's Laboratories Limited STABLE LIQUID PHARMACEUTICAL COMPOSITION
US20200352857A1 (en) * 2017-04-28 2020-11-12 Amgen Inc. Excipients to reduce the viscosity of antibody formulations and formulation compositions
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
BR112019022873A8 (pt) 2017-05-02 2023-04-11 Merck Sharp & Dohme Formulação, e, vaso ou dispositivo de injeção.
SG11202003754YA (en) 2017-05-16 2020-05-28 Bhamis Research Laboratory Pvt Ltd High concentration protein formulations with reduced viscosity
EP3646887A4 (en) * 2017-06-30 2021-03-24 Korea Advanced Institute of Science and Technology CONJUGATE OF VEGF GRAB PROTEIN AND MEDICINAL PRODUCTS AND USES THEREOF
JP2020531521A (ja) * 2017-08-22 2020-11-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗アルファ（ｖ）ベータ（６）抗体を含有する医薬組成物及び投薬計画
RU2020112302A (ru) 2017-09-05 2021-10-06 Мерк Шарп И Доум Корп. Соединения для уменьшения вязкости биологических композиций
KR20200085292A (ko) * 2017-11-07 2020-07-14 알파코어 파마 엘엘씨 심장 질병, 심혈관 질병 및 관련 질환 및 증상을 치료하고 그로부터 보호하는 방법
WO2019099837A1 (en) * 2017-11-17 2019-05-23 President And Fellows Of Harvard College Ionic liquids for internal delivery
CN108096185A (zh) * 2017-12-20 2018-06-01 珠海冀百康生物科技有限公司 一种速效胰岛素制剂及其制备方法
KR20230018549A (ko) * 2018-03-07 2023-02-07 코메라 라이프 사이언시스, 인코포레이티드 단백질 제형을 위한 부형제 화합물
BR112020021094A2 (pt) * 2018-04-16 2021-02-23 Merck Patent Gmbh redução da viscosidade de formulações de proteínas altamente concentradas
CN108671229B (zh) * 2018-05-08 2022-03-25 华博生物医药技术（上海）有限公司 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂
US11730698B2 (en) * 2018-07-19 2023-08-22 Celltrion Inc. Stable liquid pharmaceutical preparation
MX2021005910A (es) * 2018-11-21 2021-08-16 Regeneron Pharma Formulacion de proteina de alta concentracion.
US11058770B1 (en) * 2019-01-24 2021-07-13 United States Of America As Represented By The Secretary Of The Air Force Ultrastable antibody ionic liquids
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
EP3771463A1 (en) 2019-07-29 2021-02-03 Ludwig-Maximilians-Universität München Stabilizing therapeutic proteins with piperazin- or morpholine-containing zwitterionic buffering substances
US20220331430A1 (en) * 2019-09-17 2022-10-20 Merck Patent Gmbh Camphorsulfonic acid and combinations thereof with cationic excipients as viscosity reducing agents in high concentrated protein formulations
US11684594B2 (en) 2020-05-12 2023-06-27 President And Fellows Of Harvard College Antifungal prophylaxis for cornea
EP4208160A1 (en) * 2020-09-01 2023-07-12 I2O Therapeutics, Inc. Ionic liquid formulations for treating diabetes
CN113249358B (zh) * 2021-05-14 2022-10-14 天津大学 一种利用离子液体调控溶菌酶晶型的方法
WO2023278821A2 (en) * 2021-07-01 2023-01-05 Upkara, Inc. Superconcentrated formulations of bioactive agents
CN115350330B (zh) * 2022-09-01 2023-10-20 北京化工大学 一种负电性小分子调控的表面在蛋白差异性黏附上的应用

Family Cites Families (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US190082A (en) 1877-04-24 Improvement in apparatus for cooling liquids
GB750373A (en) 1953-01-15 1956-06-13 Pfizer & Co C Improvements in or relating to injectable suspension of penicillin salts
DK128416B (da) 1964-08-13 1974-04-29 Ciba Geigy Ag Analogifremgangsmåde til fremstilling af adrenocorticotropt aktive nonadecapeptidamider eller syreadditionssalte eller kompleksforbindelser deraf.
BE757195A (fr) 1969-10-07 1971-03-16 Century Disposable Devices Seringue servant a injecter un melange fraichement prepare de poudre etde liquide
JPS5270014A (en) 1975-12-05 1977-06-10 Senju Pharma Co Stabilization of pyrido*3*22a*phenoxadine compounds
US4171698A (en) 1977-08-15 1979-10-23 Abbott Laboratories Prefilled two-compartment syringe
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
ATE124999T1 (de) 1985-03-15 1995-07-15 Antivirals Inc Immunotestmittel für polynukleotid und verfahren.
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5001000A (en) 1988-09-26 1991-03-19 E. I. Du Pont De Nemours And Company Process for forming a composite structure of thermoplastic polymer and sheet molding compound
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
JPH03190823A (ja) 1989-12-21 1991-08-20 Snow Brand Milk Prod Co Ltd エリスロポエチン皮下又は筋肉投与剤
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
US5334162A (en) 1993-03-15 1994-08-02 Eli Lilly And Company Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
DE4331012A1 (de) 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
JP3524974B2 (ja) * 1994-12-26 2004-05-10 ブラッコ インターナショナル ビーヴィ プレフィルドシリンジおよびその包装体
US5569193A (en) 1995-03-22 1996-10-29 Abbott Laboratories Syringe system accommodating separately storable prefilled containers for two constituents
US5779668A (en) 1995-03-29 1998-07-14 Abbott Laboratories Syringe barrel for lyophilization, reconstitution and administration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DE19617369A1 (de) 1996-04-30 1997-11-06 Immuno Ag Lagerstabile Fibrinogen-Präparate
US6184037B1 (en) 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US5819998A (en) 1996-09-30 1998-10-13 Everything Kids Knapsack with simulated basketball court
IN184589B (sl) 1996-10-16 2000-09-09 Alza Corp
US5819988A (en) 1997-04-01 1998-10-13 Sawhney; Ravi K. Double-barreled syringe with detachable locking mixing tip
US6065645A (en) 1997-04-01 2000-05-23 Discus Dental Impressions, Inc. Double-barreled syringe with detachable locking mixing tip
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US5786571A (en) 1997-05-09 1998-07-28 Lexmark International, Inc. Wrapped temperature sensing assembly
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP1029548B1 (en) * 1997-10-15 2007-04-04 Asahi Kasei Pharma Corporation Method for keeping the quality of aqueous parenteral solution of thrombomodulin in storage and distribution
EP1043586B1 (en) 1997-10-22 2007-03-21 Chugai Seiyaku Kabushiki Kaisha METHOD OF SCREENING TGF-beta INHIBITORY SUBSTANCES
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
FR2794649B1 (fr) 1999-06-11 2003-04-11 Solutions Biomateriau a base d'un derive de dextrane insolubilise et d'un facteur de croissance, son procede de preparation et ses applications
AUPQ132599A0 (en) 1999-07-01 1999-07-22 Commonwealth Scientific And Industrial Research Organisation Nasogastric enteral formulations
US7030097B1 (en) 1999-07-14 2006-04-18 Cornell Research Foundation, Inc. Controlled nucleic acid delivery systems
EP1072323B1 (de) 1999-07-29 2003-09-10 Wilhelm A. Keller Kartuschen-Austraggerät mit Antrieb für dynamischen Mischer
BR0014486A (pt) 1999-10-04 2002-09-17 Chiron Corp Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
US6394314B1 (en) 1999-10-12 2002-05-28 Discus Dental Impressions, Inc. Double-barreled syringe with detachable locking mixing tip
US6443612B1 (en) 1999-12-02 2002-09-03 Wilhelm A. Keller Dynamic mixer
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
CA2423227C (en) * 2000-10-12 2011-11-29 Genentech, Inc. Reduced-viscosity concentrated protein formulations
JP4434583B2 (ja) 2000-11-30 2010-03-17 バイオバルブ テクノロジーズ インコーポレイテッド 注射システム
PT1407044E (pt) 2000-12-01 2008-01-02 Max Planck Ges Zur Forderung W Moléculas curtas de arn que medeiam a interferência de arn
US20040110669A1 (en) 2001-05-16 2004-06-10 Kakkis Emil D. Destruction of prions using vibriolysin or variants thereof
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
JP4317010B2 (ja) 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
WO2003011783A2 (en) 2001-08-02 2003-02-13 3M Innovative Properties Company Method of making amorphous materials and ceramics
JP4167820B2 (ja) 2001-10-19 2008-10-22 アルインコ株式会社 デッキプレート走行台車
GB0212405D0 (en) * 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use
EP1526835B1 (en) * 2002-07-31 2008-04-23 ALZA Corporation Injectable depot compositions and uses thereof
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
EP2177620B1 (en) 2003-03-05 2014-11-19 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
NZ542867A (en) 2003-03-31 2009-02-28 Durect Corp Non-aqueous single phase vehicles and formulations utilizing such vehicles involving a polymer
KR101208291B1 (ko) * 2003-04-04 2012-12-05 노파르티스 아게 고농도 항체 및 단백질 제형
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
US7341843B2 (en) 2003-04-11 2008-03-11 Allergan, Inc. Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
CA2522544A1 (en) * 2003-04-15 2004-10-28 Ista Pharmaceuticals, Inc. Process for isolating and purifing ovine hyaluronidase
US20040247672A1 (en) 2003-05-16 2004-12-09 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
US20070184084A1 (en) 2003-05-30 2007-08-09 Guohua Chen Implantable elastomeric caprolactone depot compositions and uses thereof
EP2392923B1 (en) 2003-06-18 2014-05-21 The Scripps Research Institute Method of producing proteins comprising unnatural amino acid
AU2004251742A1 (en) 2003-06-23 2005-01-06 Sanofi Pasteur, Inc. Immunization method against Neisseria meningitidis serogroups A and C
CN1206344C (zh) 2003-07-28 2005-06-15 中国海洋大学 一种用细菌生产岩藻聚糖硫酸酯酶的方法
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
WO2005094785A2 (en) 2003-09-17 2005-10-13 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
GB0403938D0 (en) 2004-02-21 2004-03-24 West Pharm Serv Drug Res Ltd Chitosan containing solution
CN101001878B (zh) 2004-06-21 2012-09-26 米德列斯公司 干扰素α受体1抗体及其用途
ES2346212T3 (es) * 2004-11-25 2010-10-13 Chr. Hansen A/S Metodo para la preparacion de una laca de acido carminico.
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060141040A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
KR20070107079A (ko) * 2005-01-28 2007-11-06 와이어쓰 안정화된 액체 폴리펩타이드 제형
CN101326275B (zh) 2005-10-07 2013-06-05 阿拉巴马大学 多功能离子液体组合物
CN100416002C (zh) * 2005-10-26 2008-09-03 曲新华 污水再生利用装置
AR058567A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Formulaciones de proteinas estables
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
US7390786B2 (en) 2005-12-21 2008-06-24 Wyeth Protein formulations with reduced viscosity and uses thereof
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
CN1823768A (zh) * 2006-01-09 2006-08-30 徐新盛 西咪替丁冻干组合物
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
DE102006005094A1 (de) 2006-02-04 2007-08-09 Degussa Gmbh Titandioxid und Polycarboxylatether enthaltende Dispersion
ITMI20061030A1 (it) 2006-05-26 2007-11-27 Altergon Sa Nuova composizione comprendente glicosamminoglicani a viscosita' controllata e uso di tale composizione nella terapuia della cistite cronica
CU23526B6 (es) * 2006-10-03 2010-05-19 Ct Ingenieria Genetica Biotech Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética
WO2008092084A2 (en) 2007-01-26 2008-07-31 Centocor, Inc. Injectable non-aqueous suspension with high concentration of therapeutic agent
CN103961315A (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
WO2009015367A2 (en) 2007-07-25 2009-01-29 Arizona Board Of Regents For And On Behalf Of Arizona State University Stabilizing proteins using ionic liquids
WO2009026122A1 (en) 2007-08-17 2009-02-26 Amgen Inc. Formulations of antibodies and fc-fusion molecules using polycations
CA2701032C (en) 2007-09-27 2021-01-26 Amgen Inc. Pharmaceutical formulations
KR20100093046A (ko) 2007-10-16 2010-08-24 파마시클릭스, 인코포레이티드 응고 인자 ｖｉｉａ 조절물질의 제조, 조성물 및 용도
EP2219602A1 (en) 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
KR20150080038A (ko) * 2007-11-30 2015-07-08 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
EP2234636A4 (en) 2007-12-21 2013-05-15 Lyotropic Therapeutics Inc FORMULATIONS OF STABILIZED PEPTIDES AND PROTEINS
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US20120251615A1 (en) * 2008-01-18 2012-10-04 Horst Kief Agent for intra-articular injection
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
WO2009137471A2 (en) * 2008-05-05 2009-11-12 University Of Miami Azo dye related small molecule modulators of protein-protein interactions
EP2123307A1 (en) * 2008-05-20 2009-11-25 Hexal Ag Method for reducing leachables and extractables in syringes
CA2743789C (en) 2008-11-16 2017-10-31 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
TWI342781B (en) 2008-12-01 2011-06-01 Univ China Medical Blood sugar-modulating polypeptides
EP2403874A1 (en) 2009-03-06 2012-01-11 Genentech, Inc. Antibody formulation
JP2012526121A (ja) * 2009-05-04 2012-10-25 アボツト・バイオテクノロジー・リミテツド ヒト抗ｔｎｆアルファ抗体の安定した高蛋白質濃度製剤
WO2010132047A1 (en) 2009-05-14 2010-11-18 Rensselaer Polytechnic Institute Guanosine/gmp gels and uses thereof
EP3018481B1 (en) 2009-05-20 2018-02-21 Sekisui Medical Co., Ltd. Blood coagulation time prolonging agent
EP3679942A1 (en) 2009-06-17 2020-07-15 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
EP2458990B1 (en) * 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
KR20120047995A (ko) * 2009-08-04 2012-05-14 제넨테크, 인크. 감소된 점도를 갖는 농축 폴리펩티드 제제
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
CA2774053C (en) 2009-09-17 2015-04-28 Baxter Healthcare, S.A. Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
EP2491123B1 (en) 2009-10-20 2018-04-18 The Regents of The University of California Single molecule nucleic acid nanoparticles
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CA2781467C (en) 2009-11-20 2015-10-13 Biocon Limited Formulations of antibody
WO2011069037A2 (en) 2009-12-03 2011-06-09 The University Of North Carolina At Charlotte Stabilization and storage of biological pharmaceutical compositions
EP2510096B2 (en) 2009-12-10 2018-02-07 Regents of the University of Minnesota Tal effector-mediated dna modification
EP2521528B1 (en) 2010-01-08 2014-08-20 Chanel Parfums Beauté Use of at least one extract of flowers of camellia japonica alba plena for moisturizing the skin
US9241897B2 (en) 2010-02-04 2016-01-26 Csl Behring Ag Immunoglobulin preparation
EP3708190A1 (en) 2010-02-26 2020-09-16 Novo Nordisk A/S Stable antibody containing compositions
CA2794929C (en) * 2010-03-01 2018-06-05 Progenics Pharmaceuticals, Inc. Concentrated protein formulations and uses thereof
US20130171128A1 (en) 2010-03-02 2013-07-04 Amgen Inc. Reducing viscosity of pharmaceutical formulations
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
AR080685A1 (es) 2010-03-17 2012-05-02 Abbott Res Bv Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
CA2794631A1 (en) * 2010-03-31 2011-10-06 Universite De Geneve Stabilized antibody preparations and uses thereof
CN101851267A (zh) 2010-04-22 2010-10-06 江南大学 一种抗体保护剂及其应用
MX2012012743A (es) * 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
ME02819B (me) * 2010-05-14 2018-01-20 Amgen Inc Formulacije sa visokom koncentracijom antitijela
GB201012179D0 (en) 2010-07-20 2010-09-01 Future Injection Technologies Injection device
PT2637690T (pt) * 2010-11-11 2016-12-27 Abbvie Biotechnology Ltd Formulações líquidas de anticorpo anti-tnf-alfa de concentração elevada
US8936827B2 (en) 2011-02-25 2015-01-20 Abbott Cardiovascular Systems Inc. Methods of loading a hollow stent with a drug or drug formulation
EA201391488A1 (ru) 2011-04-07 2014-01-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Композиции со сниженной вязкостью
SG193964A1 (en) 2011-04-07 2013-11-29 Glaxosmithkline Llc Formulations with reduced viscosity
RU2485133C2 (ru) * 2011-05-30 2013-06-20 Закрытое Акционерное Общество "Фарм-Синтез" Белково-полипептидный комплекс, обладающий тканеспецифическим регенеративно-репаративным и омолаживающим действием на кожную ткань, способ его получения и фармацевтическая композиция на его основе
CN102349895B (zh) * 2011-09-28 2013-04-10 海南良方医药有限公司 一种注射用西咪替丁组合物及其制备方法
EP2771298B1 (en) 2011-10-25 2017-12-13 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
KR101759694B1 (ko) * 2011-10-28 2017-07-19 인테그리티 바이오, 아이엔씨. 아미노산을 함유하는 단백질 제제
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
WO2013096835A1 (en) * 2011-12-23 2013-06-27 Abbvie Inc. Stable protein formulations
US20140370012A1 (en) * 2012-01-27 2014-12-18 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
US10316095B2 (en) 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations
WO2013173789A2 (en) 2012-05-17 2013-11-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
SG10201709555SA (en) 2012-05-18 2017-12-28 Genentech Inc High-concentration monoclonal antibody formulations
US10266850B2 (en) 2012-05-25 2019-04-23 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
KR20150024301A (ko) 2012-05-25 2015-03-06 노파르티스 아게 생물학적 치료제 및 구아니딘 또는 구아니딘 유도체를 함유하는 수성 약제학적 조성물 및 당해 조성물을 포함하는 주사제
JP6157611B2 (ja) 2012-06-21 2017-07-05 ユセベ ファルマ ソシエテ アノニム 医薬製剤
CN116622704A (zh) 2012-07-25 2023-08-22 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
CN109705218B (zh) 2012-08-09 2022-07-19 罗切格利卡特公司 Asgpr抗体及其用途
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
FR2995214B1 (fr) 2012-09-10 2014-11-21 Adocia Solution a viscosite reduite de proteine a concentration elevee
WO2014160083A1 (en) 2013-03-13 2014-10-02 Applied Cardiovascular Solutions, Llc. Methods, compositions, and devices for the occlusion of cavities and passageways
US9669242B2 (en) 2013-07-01 2017-06-06 L'oreal Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use
CN110559435B (zh) 2013-09-11 2023-10-20 伊戈尔生物药品股份有限公司 包含离子性液体的液体蛋白质制剂
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US11471479B2 (en) * 2014-10-01 2022-10-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents

Also Published As

Publication number Publication date
AU2014318725A2 (en) 2019-02-14
CN105848636B (zh) 2020-02-21
CN111202711B (zh) 2022-06-21
CN105722500A (zh) 2016-06-29
IL244430A0 (en) 2016-04-21
US20180153997A1 (en) 2018-06-07
RU2016113283A3 (sl) 2018-07-27
NZ717918A (en) 2021-05-28
CN105848636A (zh) 2016-08-10
AU2020202408B2 (en) 2023-09-21
SG11201601730TA (en) 2016-04-28
AU2020202240A1 (en) 2020-04-23
JP6768858B2 (ja) 2020-10-14
SG10201913950XA (en) 2020-03-30
EP3043774B1 (en) 2020-11-04
EP4272763A2 (en) 2023-11-08
HK1225981A1 (zh) 2017-09-22
AU2014318696A1 (en) 2016-04-07
CN111202711A (zh) 2020-05-29
US10849977B2 (en) 2020-12-01
CN110496099A (zh) 2019-11-26
AU2014318637B2 (en) 2020-01-23
CN105722501A (zh) 2016-06-29
CA2924069A1 (en) 2015-03-19
RU2016113283A (ru) 2017-10-17
RU2675824C2 (ru) 2018-12-25
WO2015038818A2 (en) 2015-03-19
CA2923844C (en) 2022-07-26
JP2019073563A (ja) 2019-05-16
KR20160055243A (ko) 2016-05-17
EP3043774A2 (en) 2016-07-20
MX2021005907A (es) 2021-06-23
SI3043776T1 (sl) 2024-03-29
US20210085792A1 (en) 2021-03-25
ES2959451T3 (es) 2024-02-26
KR102295633B1 (ko) 2021-08-30
IL275388A (en) 2020-07-30
RU2019140607A (ru) 2020-05-29
US10821184B2 (en) 2020-11-03
AU2020202408A1 (en) 2020-05-07
AU2014318725A1 (en) 2016-04-07
AU2014318725B2 (en) 2020-01-23
CN105705139A (zh) 2016-06-22
RU2710542C2 (ru) 2019-12-27
JP6774484B2 (ja) 2020-10-21
EP3043775A2 (en) 2016-07-20
JP2019178176A (ja) 2019-10-17
CN105722501B (zh) 2019-07-26
KR102435648B1 (ko) 2022-08-25
JP6941137B2 (ja) 2021-09-29
CA2923844A1 (en) 2015-03-19
US20150071922A1 (en) 2015-03-12
CN110496099B (zh) 2022-06-21
JP6469113B2 (ja) 2019-02-13
JP2020203956A (ja) 2020-12-24
ZA201802108B (en) 2022-04-28
US20210030877A1 (en) 2021-02-04
ZA201601968B (en) 2018-07-25
KR20240042200A (ko) 2024-04-01
ZA201801669B (en) 2021-07-28
EP3043776B1 (en) 2024-01-03
US20180085463A1 (en) 2018-03-29
US10821183B2 (en) 2020-11-03
JP6840797B2 (ja) 2021-03-10
AU2020202240B2 (en) 2023-02-09
SG10201913952TA (en) 2020-03-30
US20150071920A1 (en) 2015-03-12
SI3043774T1 (sl) 2021-01-29
RU2019140607A3 (sl) 2022-04-18
MX2021012049A (es) 2021-11-03
KR102289825B1 (ko) 2021-08-17
SI3043772T1 (sl) 2023-10-30
CA2924069C (en) 2021-11-02
BR112016005309A2 (pt) 2017-08-01
IL244430B (en) 2020-06-30
EP3808338A1 (en) 2021-04-21
JP2019056006A (ja) 2019-04-11
JP2016534141A (ja) 2016-11-04
MX2021012050A (es) 2021-11-03
JP2016530321A (ja) 2016-09-29
EP4272763A3 (en) 2024-02-14
US11819550B2 (en) 2023-11-21
JP2018199735A (ja) 2018-12-20
WO2015038818A3 (en) 2015-07-16
MX2016003183A (es) 2016-11-14
CA2923843A1 (en) 2015-03-19
JP6412575B2 (ja) 2018-10-24
IL244433B (en) 2020-07-30
KR102651018B1 (ko) 2024-03-27
US9833513B2 (en) 2017-12-05
WO2015038811A2 (en) 2015-03-19
AU2023200941A1 (en) 2023-03-30
JP2019142985A (ja) 2019-08-29
AU2014318691B2 (en) 2020-01-23
SG10201809401XA (en) 2018-11-29
WO2015038811A3 (en) 2015-07-23
ES2837629T3 (es) 2021-07-01
HK1225982A1 (zh) 2017-09-22
AU2020202407A1 (en) 2020-05-07
CA2923859C (en) 2021-11-23
BR112016005309A8 (pt) 2021-06-22
CN105722500B (zh) 2019-08-30
CN110559435B (zh) 2023-10-20
HK1226309A1 (zh) 2017-09-29
US20180177875A1 (en) 2018-06-28
CN105705139B (zh) 2019-07-26
US9913905B2 (en) 2018-03-13
HK1225980A1 (zh) 2017-09-22
AU2014318691A1 (en) 2016-04-07
EP3791862A1 (en) 2021-03-17
MX2016003182A (es) 2017-03-31
CA2923843C (en) 2022-07-12
EP3043772A1 (en) 2016-07-20
IL244433A0 (en) 2016-04-21
MX2021012048A (es) 2021-11-03
CA2923859A1 (en) 2015-03-19
US20180177876A1 (en) 2018-06-28
AU2014318696B2 (en) 2020-01-23
AU2023229619A1 (en) 2023-10-05
US9925263B2 (en) 2018-03-27
EP3043775B1 (en) 2020-11-04
AU2023251546A1 (en) 2023-11-16
US10179172B2 (en) 2019-01-15
SG11201601728YA (en) 2016-04-28
CN110559435A (zh) 2019-12-13
AU2014318637A1 (en) 2016-04-07
JP6564512B2 (ja) 2019-08-21
WO2015038782A1 (en) 2015-03-19
KR20210110396A (ko) 2021-09-07
ZA202102906B (en) 2023-12-20
JP2016530319A (ja) 2016-09-29
KR20220123552A (ko) 2022-09-07
US10646571B2 (en) 2020-05-12
US20210038718A1 (en) 2021-02-11
EP3043776A1 (en) 2016-07-20
ES2841134T3 (es) 2021-07-07
RU2016113385A (ru) 2017-10-16
JP2023021352A (ja) 2023-02-10
JP2016530318A (ja) 2016-09-29
JP6515105B2 (ja) 2019-05-15
KR20160054009A (ko) 2016-05-13
US20150071925A1 (en) 2015-03-12
HK1225979A1 (zh) 2017-09-22
US20150071921A1 (en) 2015-03-12
SG10201806539XA (en) 2018-08-30
EP3043772B1 (en) 2023-07-19
WO2015038777A1 (en) 2015-03-19
NZ717944A (en) 2021-06-25
AU2020202407B2 (en) 2023-07-13
NZ756260A (en) 2021-06-25
JP6463581B2 (ja) 2019-02-06
NZ756401A (en) 2021-05-28
JP7214697B2 (ja) 2023-01-30

Similar Documents

Publication Publication Date Title
IL275388A (en) Liquid protein formulations containing viscosity reducing agents
HK1222557A1 (zh) 的穩定的液體製劑
SG11201508564QA (en) Cleaning liquid composition
EP2955579A4 (en) LIQUID DEVELOPER
HUE039180T2 (hu) Folyékony mosószerkészítmény
ZA201507331B (en) Liquid cleaning composition
EP3041352B8 (en) Cleaning liquid
IL241040A0 (en) Liquid formulations of rascadotril
GB2532663B (en) Liquid mouthwash
SG11201506298YA (en) Liquid container
HK1220366A1 (zh) 蛋白製劑
EP2997039A4 (en) STABILIZED LIQUID FORMULATIONS WITH RECEPTORS
EP2830607A4 (en) POLYVINYLPYRROLIDONE-BASED ACETAMINOPHONE LIQUID FORMULATIONS
EP2997114A4 (en) COMPOSITION BASED ON IONIC LIQUID
GB201315537D0 (en) Liquid mixer
PL2865740T3 (pl) Płynny środek do szorowania
HK1179466A2 (en) Liquid container